翻訳と辞書 Words near each other ・ Kirimetiyagara ・ Kirimetiyawa ・ Kirimi Kaberia ・ Kirimiri ・ Kirimunge ・ Kirimäe ・ Kirin ・ Kirin (manga) ・ Kirin Company ・ Kirin Cup ・ Kirin Free ・ Kirin Holdings ・ Kirin Kiki ・ Kirin Open ・ Kirin-Amgen ・ Kirin-Amgen Inc v Hoechst Marion Roussel Ltd ・ Kirinda ・ Kirinda Puhulwella Divisional Secretariat ・ Kirindewela ・ Kirindiketiya ・ Kirindiwela ・ Kirindiwelpola ・ Kirindy Forest ・ Kirindy Mitea National Park ・ Kiringi ・ Kiringul ・ Kirinia ・ Kirinia roxelana ・ Kirinishiki Toshirō ・ Kirinji Dictionary Lists mini英和辞書 mini和英辞書 Webster 1913 Latin-English FOLDOC Wikipedia English ウィキペディア

翻訳と辞書　辞書検索 [ 開発暫定版 ] スポンサード リンク Kirin-Amgen Inc v Hoechst Marion Roussel Ltd ： ウィキペディア英語版 Kirin-Amgen Inc v Hoechst Marion Roussel Ltd Kirin-Amgen, Inc. v Hoechst Marion Roussel Ltd. is a decision by the House of Lords of England and Wales. The judgment was issued on 21 October 2004 and relates to the scope to be accorded to patent claims, including the doctrine of equivalents. The case and subsequent judgment affirmed principles from a prior case, Catnic Components Ltd. v. Hill & Smith Ltd. The issue was whether the claims of a European patent granted to Kirin-Amgen, Inc. were infringed by Transkaryotic Therapies Inc. and Hoechst Marion Roussel Ltd in a situation where there was a remarkable similarity between the technologies employed by the two parties for producing the hormone erythropoietin. Infringement was not found due to the language used in the claims of the Amgen patent. The reasoning in the judgment has presently formed a basis for the current practice of the UK Intellectual Property Office, and other countries that take great consideration of the legal implications of British case law, when assessing whether a patent has been infringed by a device or process which is equivalent to the patented invention. (See also Doctrine of equivalents.) ==Background== Kirin-Amgen, Inc. ("Amgen"), a Californian pharmaceutical company, was the proprietor of relating to the production of the glycoprotein hormone erythropoietin (EPO) by recombinant DNA technology. Amgen sued Transkaryotic Therapies, Inc. ("TKT") for patent infringement. TKT, a Massachusetts corporation, had also developed a method of making EPO using a process of gene activation. Hoechst Marion Roussel Ltd ("Hoechst") was sued for proposing to import TKT’s EPO into the United Kingdom. EPO, a previously known glycoprotein hormone, is made in the kidney and stimulates the production of red blood cells by the bone marrow. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Kirin-Amgen Inc v Hoechst Marion Roussel Ltd」の詳細全文を読む スポンサード リンク 翻訳と辞書 : 翻訳のためのインターネットリソース Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.